Role of denosumab in breast cancer

Expert Opinion on Biological Therapy

Volumn 9, Issue 9, 2009, Pages 1225-1233

  Bartsch, Rupert ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Denosumab; Osteoporosis; Osteoprotegerin; RANK; Zoledronic acid

Indexed keywords

AMGN 0007; AMINO TERMINAL TELOPEPTIDE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; DENOSUMAB; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

AREA UNDER THE CURVE; BONE LESION; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; JAW OSTEONECROSIS; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; FEMALE; HUMANS; RANK LIGAND;

EID: 68949159770     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903146877     Document Type: Review

References (78)

1. American Cancer Society Facts and Figures 2007. Avaiable from: http://www.cancer. org/docroot/STT/STT-0.asp [Last accessed 3 July 2009]
2. World Health Organization Facts and Figures. Avaiable from: http://www.who. int/whr/2003/en/Facts-and-Figures-en.pdf [Last accessed 3 July 2009]
3. Faneyte IF, Peterse JL Van Tinteren H, et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004;10:4457-4463
4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science (Wash DC) 1987;235:177-182
5. Paik S, Hazan R, Fisher ER, et al. Pathologic finding from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein expression in primary breast cancer. J Clin Oncol 1990;8:103-112 (Pubitemid 20032452)
6. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;4:650-655
7. Ross JS, Fletcher JA, Linette GP. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-325
8. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001;98:10869-10874 (Pubitemid 32878711)
9. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536
10. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009 (Pubitemid 35461656)
11. Solomayer EF, Diel IJ, Meyberg GC, et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000;59:271-278
12. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-1594
13. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593
14. Beslija S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007;18:215-255 (Pubitemid 46323085)
15. Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003;89:2031-2037
16. Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007;34(6 Suppl 4):17S-23S (Pubitemid 350192630)
17. Cascinu S, Graziano F, Alessandoni P, et al. Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 1998;6:139-143 (Pubitemid 28110538)
18. Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 2005;31(Suppl 3):19S-25S
19. Bell R. Efficacy of ibandronate in metastatic bone disease: review of clinical data. Oncologist 2005;10(Suppl 1):8S-13S (Pubitemid 41504871)
20. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34:452-475
21. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-691
22. Eidtmann H, Bundred NJ, Deboer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow up of ZO-FAST. Cancer Res 2009;60(Suppl 2):74S
23. Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/ osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007;92:4514-4521 (Pubitemid 350223419)
24. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-1508
25. Massey HM, Flanagan AM. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 1999;106:167-170
26. Li P, Schwarz EM, O'Keefe RJ, et al. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum 2004;50:265-276 (Pubitemid 38084312)
27. Demulder A, Takahashi S, Singer FR, et al. Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease. Endocrinology 1993;133:1978-1982 (Pubitemid 23324699)
28. Gregoretti MG, Bergui L, Aragno M, et al. Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma. Leukemia 1995;9:1392-1397
29. Terpos E, Dimopoulos MA. Myeloma bone disease: pathopysiology and management. Ann Oncol 2005;16:1223-1231 (Pubitemid 41158467)
30. Terpos E, Efstathiou E, Christoulas D, et al. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opin Biol Ther 2009;9:465-479
31. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357 (Pubitemid 30649812)
32. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-1488 (Pubitemid 32038586)
33. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176 (Pubitemid 28180851)
34. Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400 (Pubitemid 29026714)
35. Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001;44:253-259 (Pubitemid 32207017)
36. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-831 (Pubitemid 37074957)
37. Giuliano N, Colla S, Rizzoli V. Update on the pathogenesis of osteolysis in multiple myeloma patients. Acta Biomed 2004;75:143-152 (Pubitemid 40288255)
38. Orr FW, Varani J, Gondek MD, et al. Chemotactic responses of tumor cells to products of resorbing bone. Science 1979;203:176-179 (Pubitemid 9117878)
39. Kostenuik PJ, Singh G, Suyama KL, Orr FW. A quantitative model for spontaneous bone metastasis: evidence for a mitogenic effect of bone on Walker 256 cancer cells. Clin Exp Metastasis 1992;10:403-410
40. Galasko C. Mechanisms of bone destruction in the development of skeletal metastases. Nature 1976;263:507-509
41. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 2001;57:611-616
42. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001:107:1235-1244 (Pubitemid 32494540)
43. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-5445
44. Lai F, Cole-Sinclair M, Cheng WJ, et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Brit J Haematol 2004;126:192-201 (Pubitemid 38961937)
45. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-4458 (Pubitemid 30666108)
46. Chikatsu N, Takeuchi Y, Tamura Y, et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 2000;267:632-637 (Pubitemid 30076850)
47. Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 2002;198:228-236 (Pubitemid 35243881)
48. Okada T, Akikusa S, Okuno H, Kodaka M. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin Exp Metastasis 2003;20:639-646 (Pubitemid 37463901)
49. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2007;29:155-192
50. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-360 (Pubitemid 32105416)
51. Body JJ, Greipp P, Coleman RE, et al. A Phase I study of AMGN-0007 a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97:887-892 (Pubitemid 36125828)
52. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2005;19:1059-1066
53. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005;5:618-625
54. Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the faclie generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999;231:11-23
55. Kostenuik PJ, Warmington K, Grisanti M, et al. RANKL inhibition with AMG162, a fully human MAb, causes sustained suppression of bone resorption and increased BMD in knockin mice expressing humanized RANKL. J Bone Miner Res 2005;20:259S
56. Atkinson J, Cranmer P, Saunders T, et al. AMG 162, a fully human RANKL antibody, increases bone mass and bone strength in cynomolgus monkeys. J Bone Miner Res 2005;20:294S
57. Ominsky MS, Schroeder J, Smith SY, et al. Denosumab (AMG 162, a fully human RANKL antibody) increases cortical and cancellous bone mass in aged ovariectomized cynomolgus monkeys. J Bone Miner Res 2006;21:72S
58. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007;9(Suppl 1):7S
59. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-1228 (Pubitemid 43342512)
60. Yonemor K, Fujiwara Y, Minami H, et al. Phase I trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008;99:1237-1242 (Pubitemid 351676637)
61. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1959-1966
62. Peterson MC, Jang G, Kim W, et al. Selection of a phase 3 dose regimen for denosumab based on pharmacokinetic (PK), pharmacodynamic (PD), and safety data from multiple subcutaneous (SC) dosing regimens in breast cancer patients (pts) with bone metastases (BM). J Clin Oncol 2006;24(Suppl 18):abstract 3086
63. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-831 (Pubitemid 43290920)
64. Lipton A, Steger GG, Figuera J, et al. Randomized active-controlled Phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-4437 (Pubitemid 350013849)
65. Lane NE, Iannini M, Atkins C, et al. RANKL inhibition with denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:225S
66. Lipton A, Steger GG, Figuera J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008;14:6690-6696
67. Fizazi K, Lipton A, Mariette X, et al. Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-1571
68. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-4882
69. ClinicalTrials. NCT00556374. Avaiable from: http://www.clinicaltrial.gov/ [Last accessed 3 July 2009]
70. Allen MR, Iwata K, Phipps R, et al. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006;39:872-879 (Pubitemid 44311727)
71. Flick LM, Weaver JM, Ulrich-Vinther M, et al. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res 2003;21:676-684 (Pubitemid 36758211)
72. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-25194 (Pubitemid 27415705)
73. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424 (Pubitemid 29453612)
74. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323 (Pubitemid 29061638)
75. Yun TJ, Tallquist MD, Aicher A, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001;166:1482-1491 (Pubitemid 32114626)
76. Stolina M, Guo J, Faggioni R, et al. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol 2003;109:347-354 (Pubitemid 38091454)
77. Miller RE, Branstetter D, Armstrong A, et al. Receptor activator of NF-kappaB ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune response to influenza infection. J Immunol 2007;179:266-274 (Pubitemid 46986542)
78. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761 (Pubitemid 46780635)